Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 26:15:115-126.
doi: 10.2147/IJNRD.S354658. eCollection 2022.

Association Between Indoxyl Sulfate and Dialysis Initiation and Cardiac Outcomes in Chronic Kidney Disease Patients

Kullaya Takkavatakarn  1 , Jeerath Phannajit  1 , Suwasin Udomkarnjananun  1 , Suri Tangchitthavorngul  1 , Pajaree Chariyavilaskul  2   3 , Patita Sitticharoenchai  4 , Kearkiat Praditpornsilpa  1 , Somchai Eiam-Ong  1 , Paweena Susantitaphong  1   5
Affiliations

Association Between Indoxyl Sulfate and Dialysis Initiation and Cardiac Outcomes in Chronic Kidney Disease Patients

Kullaya Takkavatakarn et al. Int J Nephrol Renovasc Dis. .

Abstract

Introduction: Indoxyl sulfate, a protein-bound uremic toxin, has been reported as an atherosclerosis and fibrosis accelerator. This study aimed to determine whether serum indoxyl sulfate is associated with cardiac abnormalities, cardiovascular events, and renal progression to dialysis in patients with chronic kidney disease (CKD).

Methods: The prospective study enrolled 89 patients with CKD stage 3 to 5 patients. Serum biochemistry data and indoxyl sulfate were measured. All patients underwent echocardiographic examination. Global longitudinal strain (GLS) was calculated using two-dimensional speckle tracking. The clinical outcomes including cardiovascular event and dialysis initiation were recorded during a 2-year follow-up.

Results: Patients were divided into 2 groups based on the median value of serum indoxyl sulfate (low and high indoxyl sulfate groups). Kaplan-Meier analysis revealed that patients with higher indoxyl sulfate (≥6.124 mg/L) were significantly associated with renal progression to dialysis (p < 0.001). There was no significant difference in cardiovascular events between 2 groups (p = 0.082). In addition, serum indoxyl sulfate level was independently associated with GLS (r = 0.62; p = 0.01). The risk of cardiovascular events was significantly higher in patients with impaired GLS (>-16%) (p = 0.015).

Conclusion: Serum indoxyl sulfate level was a significant predictor for CKD progression to dialysis and was correlated with GLS, a speckle tracking echocardiography parameter representing early LV systolic dysfunction. Furthermore, GLS was associated with cardiovascular events in CKD patients. Serum indoxyl sulfate measurement may help to identify the high dialysis and cardiovascular risk CKD patients beyond traditional risk factors.

Keywords: cardiovascular events; chronic kidney disease; echocardiographic parameters; indoxyl sulfate; renal outcomes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest in this work.

Figures

None
Graphical abstract
Figure 1
Figure 1
Linear regression curve. Relationship between serum levels of indoxyl sulfate and global longitudinal strain.
Figure 2
Figure 2
Kaplan–Meier curves of cumulative event-free survival for dialysis according to low- and high- indoxyl sulfate group.
Figure 3
Figure 3
Kaplan–Meier curve of the cumulative cardiovascular event-free survival stratified by GLS (preserved and impaired GLS groups).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Carney EF. The impact of chronic kidney disease on global health. Nat Rev Nephrol. 2020;16(5):251. doi:10.1038/s41581-020-0268-7 - DOI - PubMed
    1. System USRD. 2020 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2020.
    1. Jankowski J, Floege J, Fliser D, Bohm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143(11):1157–1172. doi:10.1161/CIRCULATIONAHA.120.050686 - DOI - PMC - PubMed
    1. Valdivielso JM, Rodriguez-Puyol D, Pascual J, et al. Atherosclerosis in chronic kidney disease: more, less, or just different? Arterioscler Thromb Vasc Biol. 2019;39(10):1938–1966. doi:10.1161/ATVBAHA.119.312705 - DOI - PubMed
    1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–1305. doi:10.1056/NEJMoa041031 - DOI - PubMed